Abstract:
Human cytomegalovirus (HCMV) is an important pathogen in immuncompromised persons. Patients who have undergone bone marrow transplantation can have severe and sometimes fatal infections in the posttransplant period.
The management of HCMV disease include prophylactic, suppressive, and preemptive treatment.
The cellular and the humoral immune responses are likely to be involved in the control of HCMV infection.
In recent years, there has been an accumulation of evidence suggesting that strain-specific differences might contribute to the clinical course of HCMV infection.
Likewise, survival rates of bone marrow transplant recipients with HCMV infection have been linked to specific genotypes in the envelope glycoprotein H (gH) and glycoprotein B (gB).